Qalsody (Tofersen) Patent Expiration, LOE Window & CMS Spending
Qalsody (Tofersen) by Biogen: FDA Orange Book core substance LOE 2035-04-01, 0 AB generics, $1.8M 2024 CMS Part D & Medicaid spend, and $14,230 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Biogen |
| FDA Application & Pathway | N215887 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2035-04-01 |
| Last Listed Patent or Exclusivity Date | 2035-04-01 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.8M |
| 2024 Medicare Part D Spend | $1.1M |
| 2024 Medicaid Spend | $690K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($14,230 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.